FREE TREATMENT REPORT
See ratings and reviews when you sign up for an account.
Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine
This study is currently Recruiting
July 2011 By Neurology Group of Bergen County, P.A.
First Recieved on June 15, 2010
Last Updated on July 19, 2011
This study is investigating the effect of sustained-release guanfacine (Intuniv) on
language-based learning skills in children age 6-12 who are diagnosed with attention deficit
hyperactivity disorder (ADHD).
||Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Resources/Links provided by NLM:
|Study Start Date:
|Estimated Primary Completion Date:
Single arm - all patients treated with study drug. Comparison is against pre-treatment performance.
|Drug:Guanfacine (sustained release)|
Treated with study drug once screening and initial testing is completed (see protocol above)
|Ages Eligible for Study:||6 Years|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||Accepts Healthy Volunteers|
Inclusion Criteria: Diagnosis of ADHD-inattentive or combined type.
- Intelligence (IQ) below 85 as determined by formal testing.
- Identified or suspected genetic syndromes.
- Autism or other pervasive developmental disorders.
- Psychiatric disorders other than ADHD and oppositional defiant disorder.
- Heart, liver or renal disease.
- Epilepsy or non-febrile seizure history.
- Cardiac arrhythmia, bradycardia, or syncope.
- Any other condition considered to be potentially exacerbated or endangered by
treatment with an alpha-2 agonist drug.